AIMS: Isolated retroperitoneal recurrence (IRR) in renal cancer patients after radical nephrectomy (RN) is a rare event and poses a therapeutic dilemma. We evaluated oncologic outcomes in surgically treated patients with IRR and established prognostic factors associated with survival. The benefit of metastasis-directed therapy (MDT) in those with clinical progression after extirpation of IRR was assessed. METHODS: This was a retrospective single-institutional study in which 60 renal cancer patients after previous RN underwent surgery for suspicion of IRR within the period of 2004-2019; in 55 of them, RCC recurrence was histologically confirmed. No patient had distant metastatic disease at the time of IRR diagnosis. In cases of clinical progression after IRR surgery, MDT (metastasectomy, stereotactic radiotherapy) was selectively used. Kaplan-Meier curves were used to estimate survival outcomes. Univariable and multivariable Cox proportional hazards regression analyses were used to evaluate associations between clinicopathological parameters and cancer-specific survival. RESULTS: Median age at IRR diagnosis was 64 years (range 23-81). IRR was diagnosed at a median of 42 months (IQR 19-99) after RN. Surgical complications of grade 3-5 after IRR extirpation were rare (7%). Median follow-up time was 50 months (IQR 19-80). Five-year recurrence-free survival and cancer-specific survival rates were 32% and 66%, respectively. Radiographic progression was observed in 34 (62%) patients at a median of 11 months after IRR surgery, out of which 22 patients (40%) underwent MDT. When compared with 12 patients without MDT, the MDT patients had a prolonged median time to systemic treatment of 58 (vs. 16 months), and median cancer-specific survival of 88 (vs. 46 months). Upon multivariable analysis, the interval from nephrectomy ≤12 months (HR 7.77), tumour grade 3-4 (HR 13.24) and female sex (HR 7.42) were determined to be independent prognostic factors of cancer-related mortality. CONCLUSION: Aggressive surgical therapy of IRR is feasible with relatively low morbidity. More than half of the patients experience long-term survival. The interval from nephrectomy to IRR less than 12 months, tumour grade 3-4 and female sex were negative prognostic predictors. In the case of progression, metastasis-directed therapy may prolong the interval to initiation of systemic treatment.

Department of Comprehensive Cancer Care Faculty of Medicine Masaryk University Brno Czech Republic

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno Czech Republic

Department of Urologic Oncology Clinic of Surgical Oncology Masaryk Memorial Cancer Institute Brno Czech Republic

Faculty of Medicine Institute of Biostatistics and Analyses Masaryk University Brno Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc22019345

003      

CZ-PrNML

005      

20240528095041.0

007      

ta

008      

220720s2022 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.urolonc.2021.11.028 $2 doi

035    __

$a (PubMed)34961683

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Staník, Michal $u Department of Urologic Oncology, Clinic of Surgical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Electronic address: stanik@mou.cz

245    10

$a Oncological outcomes of surgery for isolated retroperitoneal recurrence in renal cancer patients after radical nephrectomy / $c M. Staník, A. Poprach, S. Littnerová, I. Čapák, M. Hulová, N. Šebová, R. Lakomý, J. Jarkovský, J. Doležel

520    9_

$a AIMS: Isolated retroperitoneal recurrence (IRR) in renal cancer patients after radical nephrectomy (RN) is a rare event and poses a therapeutic dilemma. We evaluated oncologic outcomes in surgically treated patients with IRR and established prognostic factors associated with survival. The benefit of metastasis-directed therapy (MDT) in those with clinical progression after extirpation of IRR was assessed. METHODS: This was a retrospective single-institutional study in which 60 renal cancer patients after previous RN underwent surgery for suspicion of IRR within the period of 2004-2019; in 55 of them, RCC recurrence was histologically confirmed. No patient had distant metastatic disease at the time of IRR diagnosis. In cases of clinical progression after IRR surgery, MDT (metastasectomy, stereotactic radiotherapy) was selectively used. Kaplan-Meier curves were used to estimate survival outcomes. Univariable and multivariable Cox proportional hazards regression analyses were used to evaluate associations between clinicopathological parameters and cancer-specific survival. RESULTS: Median age at IRR diagnosis was 64 years (range 23-81). IRR was diagnosed at a median of 42 months (IQR 19-99) after RN. Surgical complications of grade 3-5 after IRR extirpation were rare (7%). Median follow-up time was 50 months (IQR 19-80). Five-year recurrence-free survival and cancer-specific survival rates were 32% and 66%, respectively. Radiographic progression was observed in 34 (62%) patients at a median of 11 months after IRR surgery, out of which 22 patients (40%) underwent MDT. When compared with 12 patients without MDT, the MDT patients had a prolonged median time to systemic treatment of 58 (vs. 16 months), and median cancer-specific survival of 88 (vs. 46 months). Upon multivariable analysis, the interval from nephrectomy ≤12 months (HR 7.77), tumour grade 3-4 (HR 13.24) and female sex (HR 7.42) were determined to be independent prognostic factors of cancer-related mortality. CONCLUSION: Aggressive surgical therapy of IRR is feasible with relatively low morbidity. More than half of the patients experience long-term survival. The interval from nephrectomy to IRR less than 12 months, tumour grade 3-4 and female sex were negative prognostic predictors. In the case of progression, metastasis-directed therapy may prolong the interval to initiation of systemic treatment.

650    _2

$a dospělí $7 D000328

650    _2

$a senioři $7 D000368

650    _2

$a senioři nad 80 let $7 D000369

650    12

$a karcinom z renálních buněk $x patologie $7 D002292

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    12

$a nádory ledvin $x patologie $7 D007680

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a lidé středního věku $7 D008875

650    _2

$a lokální recidiva nádoru $x patologie $x chirurgie $7 D009364

650    _2

$a nefrektomie $7 D009392

650    12

$a retroperitoneální nádory $x sekundární $7 D012186

650    _2

$a retrospektivní studie $7 D012189

650    _2

$a mladý dospělý $7 D055815

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Poprach, Alexander $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Electronic address: poprach@mou.cz

700    1_

$a Littnerová, Simona $u Faculty of Medicine, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic. Electronic address: littnerova@iba.muni.cz

700    1_

$a Čapák, Ivo $u Department of Urologic Oncology, Clinic of Surgical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Electronic address: capak@mou.cz

700    1_

$a Hulová, Markéta $u Department of Urologic Oncology, Clinic of Surgical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Electronic address: marketa.hulova@mou.cz

700    1_

$a Šebová, Natália $u Department of Urologic Oncology, Clinic of Surgical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Electronic address: natalia.sebova@mou.cz $7 xx0317324

700    1_

$a Lakomý, Radek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Electronic address: lakomy@mou.cz

700    1_

$a Jarkovský, Jiří $u Faculty of Medicine, Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic. Electronic address: jarkovsky@iba.muni.cz

700    1_

$a Doležel, Jan, $d 1956- $u Department of Urologic Oncology, Clinic of Surgical Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic. Electronic address: dolezel@mou.cz $7 xx0064982

773    0_

$w MED00008671 $t Urologic oncology $x 1873-2496 $g Roč. 40, č. 3 (2022), s. 111.e27-111.e34

856    41

$u https://pubmed.ncbi.nlm.nih.gov/34961683 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20220720 $b ABA008

991    __

$a 20240528095038 $b ABA008

999    __

$a ok $b bmc $g 1822796 $s 1170588

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2022 $b 40 $c 3 $d 111.e27-111.e34 $e 20211224 $i 1873-2496 $m Urologic oncology $n Urol Oncol $x MED00008671

LZP    __

$a Pubmed-20220720